 It's for people with what they say mild cognitive decline. So it's people who show some early signs of cognitive decline. And also patients need to have confirmed amyloid in their brains. They need to get imaging to confirm that they have amyloid in their brain. Finally, Elaine, is there a sense in the community that the pharmaceutical industry may have turned a page here that there is more progress to come going forward?